### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * SULLIVAN GREGORY M			2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306			3. Date of Earliest Transaction (Month/Day/Year) 09/30/2015						X Officer (give title below) Other (specify below)  Chief Medical Officer						
(Street) NEW YORK, NY 10022			_x_						. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
	(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disp					ed, Dispo	osed of, or Beneficially Owned				
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deen Execution any (Month/D	n Date, if	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of H	Beneficial	lly Owned Following Transaction(s)		6. Ownership Form: Direct (D)	Beneficial Ownership
						Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common value	Stock, \$0.	001 par	09/30/2015			P		5,000	1 1	\$ 5.18	16,925			D	
				erivative e.g., puts,							y Owned				
Security	Conversion or Exercise	3. Transactio Date (Month/Day/	n 3A. Deemed Execution Day	e.g., puts, of 4. Ite, if Tran	nsaction	rrants, o 5. Number of Derivativ	red, Di otions er 6. D and e (Mc	tained in form distinction dis	this for plays a of, or Bendible securities below the Date	neficially rities) 7. Tit Amore Unde	not requality valid y Owned the and unt of erlying	8. Price of Derivative Security	Securities	of 10. Owners: Form of	
(Instr. 3)	Price of Derivative Security		(Month/Day/	rear) (IIIs	,	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			(	Secui (Instr 4)	. 3 and	(Instr. 5)	Beneficially Owned Following Reported Transaction (Instr. 4)	Security Direct ( or Indire	(Instr. 4)
				Со	ode V	(A) (D			Expiratio Date	Title	Amount or Number of Shares				
Repor	ting O	wners													
Reporting Owner Name / Address				Relationships											
SULLIVAN GREGORY M C/O TONIX PHARMACEUTICALS HOLDING CORP.			Directo	r 10% C	Owner	Officer	Madiaa	1.065 -	Othe	r					

## **Signatures**

NEW YORK, NY 10022

/s/ Leland Gershell, Attorney-in-Fact	09/30/2015			
**Signature of Reporting Person	Date			

# **Explanation of Responses:**

509 MADISON AVENUE, SUITE 306

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Chief Medical Officer

